8-K: Biogen Exceeds 2025 EPS Guidance, Forecasts 2026 Revenue Decline

Biogen reported strong fourth quarter and full year 2025 financial results, surpassing its full-year Non-GAAP diluted EPS guidance, while projecting a mid-single digit revenue decline for 2026.

Summary

• Total revenue for the fourth quarter of 2025 was $2.3 billion, a 7% decrease year-over-year.
• Full year 2025 total revenue reached $9.9 billion, representing a 2% increase year-over-year.
• GAAP diluted EPS for Q4 2025 was $(0.33), while full year 2025 GAAP diluted EPS was $8.79.
• Non-GAAP diluted EPS for Q4 2025 was $1.99, and full year 2025 Non-GAAP diluted EPS was $15.28, exceeding the upper end of the company's guidance range of $14.50 to $15.00.
• Revenue from growth products increased 6% year-over-year in Q4 2025 and 19% for the full year 2025, offsetting declines in multiple sclerosis products (excluding VUMERITY).
• LEQEMBI's fourth quarter global in-market sales were approximately $134 million, up 54% year-over-year, with U.S. sales of approximately $78 million.
• SKYCLARYS grew global patients on therapy by approximately 30% in 2025, with Q4 U.S. revenue of approximately $89 million and ex-U.S. revenue of approximately $44 million.
• ZURZUVAE generated approximately $66 million in revenue during Q4 2025, demonstrating strong continued demand growth.
• SPINRAZA revenue declined 15% year-over-year in Q4 2025, primarily due to timing of shipments outside the U.S., with full year revenue down 2% year-over-year.
• The FDA granted Priority Review for LEQEMBI IQLIK subcutaneous treatment initiation, with a PDUFA date of May 24, 2026.
• FDA Breakthrough Therapy Designation was granted for litifilimab in cutaneous lupus (CLE).
• High dose regimen of SPINRAZA was approved in Japan and the E.U., with a U.S. FDA PDUFA date of April 3, 2026.
• A Phase 1 study was initiated for BTK degrader (BIIB145) targeting autoimmune diseases.
• Full year 2026 Non-GAAP diluted EPS is expected to be between $15.25 and $16.25.
• Total revenue for full year 2026 is expected to decline by a mid-single digit percentage compared to full year 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by strong performance in new growth products and exceeding EPS guidance, despite anticipated overall revenue decline in 2026 and ongoing challenges in the MS franchise.

Positives

• Full year 2025 Non-GAAP diluted EPS of $15.28 exceeded the upper end of the company's guidance range of $14.50 to $15.00.
• Revenue from growth products increased 19% year-over-year for the full year 2025, successfully offsetting the year-over-year revenue decline from multiple sclerosis products (excluding VUMERITY).
• LEQEMBI global in-market sales grew significantly by 54% year-over-year in Q4 2025, reaching $134 million.
• SKYCLARYS demonstrated strong patient growth, with global patients on therapy increasing by approximately 30% in 2025.
• ZURZUVAE showed strong continued demand growth, contributing approximately $66 million in Q4 2025 revenue.
• The FDA granted Priority Review for LEQEMBI IQLIK subcutaneous treatment initiation, indicating a potentially faster path to market.
• Litifilimab received FDA Breakthrough Therapy Designation for cutaneous lupus (CLE), highlighting its potential in an area with no targeted treatment options.
• High dose SPINRAZA received approvals in Japan and the E.U., expanding its market reach and treatment options.
• Initiation of a Phase 1 study for BTK degrader (BIIB145) signals continued pipeline innovation in autoimmune diseases.
• Full year 2025 free cash flow was approximately $2.1 billion, demonstrating strong cash generation.

Negatives

• Total revenue for Q4 2025 declined by 7% year-over-year to $2.3 billion.
• GAAP diluted EPS for Q4 2025 was $(0.33), a significant decrease from $1.83 in Q4 2024.
• Non-GAAP diluted EPS for Q4 2025 declined by 42% year-over-year to $1.99.
• Multiple Sclerosis (MS) product revenue declined by 14% in Q4 2025 and 7% for the full year 2025.
• SPINRAZA revenue declined 15% year-over-year in Q4 2025, impacted by the timing of shipments outside the U.S.
• Biosimilars revenue declined by 16% in Q4 2025 and 8% for the full year 2025.
• Full year 2026 total revenue is expected to decline by a mid-single digit percentage compared to 2025.
• Full year 2025 GAAP cost of sales was negatively impacted by a pre-tax charge related to a judgment on Genentech's claim for past royalties and interest on TYSABRI sales.
• Q4 2025 GAAP other expense included approximately $131 million related to litigation matters.
• An impairment charge of approximately $52.9 million related to a Reata lease was recorded in Q4 2025.

Risks

• Substantial dependence on revenue from existing products and payments under licensing, collaboration, acquisition, or divestiture agreements.
• Uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products.
• Potential impact of increased product competition in the biopharmaceutical and healthcare industry, including from new originator therapies, generics, prodrugs, and biosimilars.
• Difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for products.
• Dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products.
• Risks associated with current and potential future healthcare reforms.
• Failure to obtain, protect, and enforce data, intellectual property, and other proprietary rights, and risks related to intellectual property claims and challenges.
• The risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials, or that early-stage success may not predict later-stage results.
• Risks associated with clinical trials, including managing activities, unexpected concerns from additional data, and regulatory authorities requiring more information or delaying/failing to approve drug candidates.
• The occurrence of adverse safety events, restrictions on product use, or product liability claims.
• Risks relating to technology, including the incorporation of new technologies such as artificial intelligence into processes.
• Risks related to the use of information technology systems and potential impacts of breakdowns, interruptions, invasions, corruptions, data breaches, or other cybersecurity incidents.
• Problems with manufacturing capacity, including the ability to manufacture products efficiently or adequately address global bulk supply risks.
• Risks relating to management, personnel, and other organizational changes, including the ability to attract, retain, and motivate qualified individuals.
• Risks related to the failure to comply with current and new legal and regulatory requirements, including judicial decisions, accounting standards, and tariff or trade restrictions.
• Risks of doing business internationally, including geopolitical tensions, acts of war, and large-scale crises.
• Risks relating to the distribution and sale by third parties of counterfeit or unfit versions of products.
• Fluctuations in operating results, access to capital and credit markets, and the market, interest, and credit risks associated with the investment portfolio.
• Risks relating to share repurchase programs and change in control provisions in certain collaboration agreements.
• Fluctuations in the effective tax rate and obligations in various jurisdictions, and environmental risks.

Future Outlook

Biogen anticipates continued business momentum and financial discipline in 2026. The company projects full year 2026 Non-GAAP diluted EPS to be between $15.25 and $16.25. Total revenue for 2026 is expected to decline by a mid-single digit percentage compared to 2025, primarily driven by further declines in multiple sclerosis product revenue (excluding VUMERITY), which are expected to be partially offset by increases from growth products. The company also looks forward to data from two Phase 3 studies in lupus for litifilimab in Q4 2026, with 10 additional potentially registrational studies across its pipeline expected to read out sequentially over the next four years, aiming to drive meaningful innovation and long-term shareholder value.

Management Comments

• "Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise."
• "Our pipeline momentum continues with a strong start in 2026, with the FDA recently granting Priority Review for LEQEMBI IQLIK initiation and Breakthrough Therapy Designation for litifilimab in CLE."
• "These milestones highlight both the innovative and differentiated value of our medicines and the strength of our late-stage pipeline."
• "Going into 2026, we are looking forward to data from two Phase 3 studies in lupus for litifilimab, with 10 additional potentially registrational studies across our pipeline expected to read out sequentially over the next four years."
• "This multi-year registrational data flow has the potential to drive meaningful innovation for patients and long-term value for shareholders."

Industry Context

StockSavvy.ai notes that Biogen's strategy of leveraging new growth products like LEQEMBI, SKYCLARYS, and ZURZUVAE to offset declines in its established Multiple Sclerosis franchise is a common approach in the mature pharmaceutical industry. The focus on late-stage pipeline assets, particularly in neurology and autoimmune diseases, positions Biogen to potentially capture new market share in areas with unmet medical needs, aligning with broader industry trends towards specialized therapies. The FDA's Priority Review and Breakthrough Therapy Designations underscore the potential of these pipeline assets in a competitive landscape.

Legal Proceedings

• Approximately $131 million related to litigation matters was included in Q4 2025 GAAP other expense.
• A pre-tax charge related to a judgment on Genentech's claim for past royalties and interest on sales of TYSABRI impacted full year 2025 GAAP cost of sales.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from pipeline progression and exceeding EPS guidance, but also risks from anticipated revenue decline and ongoing litigation matters.
• Patients: New treatment options and formulations (LEQEMBI IQLIK, litifilimab, high dose SPINRAZA) could improve patient care and access.
• Employees: The 'Fit for Growth' initiative implies cost-saving measures, which could impact employees, though there is also increased investment in late-stage programs.
• Customers/Prescribers: Continued availability and growth of key products like LEQEMBI, SKYCLARYS, and ZURZUVAE, offering new therapeutic options.
• Collaborators: Ongoing collaborations with Samsung Bioepis and Supernus Pharmaceuticals, Inc. continue to generate profit sharing expenses.

Next Steps

• PDUFA date for LEQEMBI IQLIK subcutaneous treatment initiation on May 24, 2026.
• U.S. FDA PDUFA date for high dose SPINRAZA on April 3, 2026.
• Litifilimab Phase 3 systemic lupus (SLE) studies expected to read out in Q4 2026.
• 10 additional potentially registrational studies across the pipeline expected to read out sequentially over the next four years.
• Conference call and webcast for Q4 and FY 2025 results on February 6, 2026.

Key Dates

Recommendation

While Biogen exceeded its 2025 Non-GAAP EPS guidance and demonstrated strong growth in its newer products, the projected mid-single digit revenue decline for 2026 and ongoing challenges in the established MS franchise present headwinds. The robust late-stage pipeline offers future potential, but significant data readouts are still some time away. Investors should hold, monitoring the execution of the "Fit for Growth" initiative, the performance of growth products, and the progress of the pipeline to assess long-term value creation against the backdrop of declining legacy revenues.

Keywords

Biogen, BIIB, Biotechnology, Pharmaceuticals, Earnings, Financial Results, Q4 2025, Full Year 2025, 2026 Guidance, LEQEMBI, SKYCLARYS, ZURZUVAE, SPINRAZA, Multiple Sclerosis, Alzheimer's, Rare Disease, Lupus, Clinical Trials, FDA Approval, EPS, Revenue, Pipeline